Last reviewed · How we verify
Clostridium butyricum capsules, Live
Clostridium butyricum is a live probiotic bacterium that produces butyrate to promote intestinal health and modulate the gut microbiota.
Clostridium butyricum is a live probiotic bacterium that produces butyrate to promote intestinal health and modulate the gut microbiota. Used for Diarrhea associated with dysbiosis, Irritable bowel syndrome, Inflammatory bowel conditions.
At a glance
| Generic name | Clostridium butyricum capsules, Live |
|---|---|
| Sponsor | The Affiliated Hospital of Qingdao University |
| Drug class | Probiotic |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Clostridium butyricum is a gram-positive, anaerobic bacterium that colonizes the intestinal tract and ferments dietary fiber to produce short-chain fatty acids, particularly butyrate. Butyrate serves as a primary energy source for colonocytes, strengthens the intestinal barrier function, and exerts anti-inflammatory effects. This mechanism helps restore dysbiotic microbiota balance and improve gastrointestinal health.
Approved indications
- Diarrhea associated with dysbiosis
- Irritable bowel syndrome
- Inflammatory bowel conditions
Common side effects
- Gastrointestinal disturbance
- Abdominal discomfort
- Flatulence
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: